SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Geron Corp.
GERN 1.120+1.8%Nov 21 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: bob zagorin12/8/2008 5:03:34 PM
   of 3576
 
1:31PM Geron presents interim clinical data on its telomerase inhibitor Drug trial in patients with multiple myeloma (GERN) 3.79 +0.19 : Co announces the presentation of interim data for its ongoing clinical trial of GRN163L, a telomerase inhibitor drug, in patients with relapsed and refractory multiple myeloma... Results were presented from two patients who had samples of pre- and post-treatment bone marrow collected. Both bulk and tumor stem cell-containing fractions were assessed for telomerase inhibition. Both patients received multiple infusions of GRN163L at 4.8 mg/kg and had achieved relatively high plasma levels of the drug. Telomerase activity in the bulk tumor fraction of bone marrow from those two patients decreased by 78% and 48%, respectively, after GRN163L treatment. Telomerase activity in the myeloma stem cell-containing fraction of their bone marrow declined by 33% and 63%, respectively... "These preliminary results suggest that pharmacodynamic effects in myeloma patients' tumor-containing bone marrow are evident at a GRN163L dose of 4.8 mg/kg, a well tolerated dose in these patients. Moreover, consistent with prior in vitro results, GRN163L appears to inhibit telomerase in both the bulk myeloma fraction as well as the myeloma stem cell-containing fraction in patients' bone marrow."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News